SecBot SecBot
SECBOTREPLAY Home › Report › INDP

INDP · Indaptus Therapeutics entered into an amended and restated…

Indaptus Therapeutics, Inc. · 8-K filed Sep 1, 2026 at 07:30 ET

At the news

BEARISHIMPACT 5/10

8-K filed Sep 1, 2026 at 07:30 ET

Indaptus Therapeutics entered into an amended and restated at-the-market offering agreement with H.C. Wainwright, enabling the sale of up to $100 million in common stock. This filing, combined with the prospectus supplement filed the prior day, formalizes a significant capital raise capacity for the clinical-stage biotech. The potential for substantial dilution overhangs the stock, though the company has no obligation to sell any shares.

  • Indaptus entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright for up to $100,000,000 in common stock.
  • The agreement amends and restates the prior June 1, 2022 agreement.
  • H.C. Wainwright will receive a 3.0% placement fee on shares sold as agent.
  • The company filed a related prospectus supplement on August 31, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access